Sorafenib maintenance in FLT3-ITD mutated AML after allogeneic HCT: a real-world, single-center experience

Despite allogeneic hematopoietic stem cell transplant (allo-HCT) and the development of novel FLT3 inhibitors in both induction (midostaurin) and in the relapsed/refractory setting (gilteritinib), FLT3-ITD mutated leukemia (FLT3-ITD+ AML) still represents a challenge for modern hematology. Sorafenib...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Elisa Diral, Giulia Furnari, Alessandro Bruno, Raffaella Greco, Daniela Clerici, Sarah Marktel, Francesca Farina, Sara Mastaglio, Luca Vago, Simona Piemontese, Jacopo Peccatori, Consuelo Corti, Massimo Bernardi, Fabio Ciceri, Maria Teresa Lupo-Stanghellini
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2024-06-01
Serija:	Frontiers in Oncology
Teme:	sorafenib maintenance allogeneic stem cell transplantation FLT3 ITD acute myeloid leukemia
Online dostop:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1391743/full
Oznake:	Označite Brez oznak, prvi označite!